RS62456B1 - Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva - Google Patents

Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva

Info

Publication number: RS62456B1
Authority: RS; Serbia
Prior art keywords: pyrido; isothiazolo; benzisothiazole; kras; phthalazine
Prior art date: 2016-12-22

Application number

RS20211294A

Other languages

English (en)

Inventor

Brian Alan Lanman

Victor J Cee

Alexander J Pickrell

Anthony B Reed

Kevin C Yang

David John Kopecky

Hui-Ling Wang

Patricia Lopez

Kate Ashton

Shon Booker

Christopher M Tegley

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-22

Filing date

2017-12-21

Publication date

2021-11-30

2017-12-21 Application filed by Amgen Inc filed Critical Amgen Inc

2021-11-30 Publication of RS62456B1 publication Critical patent/RS62456B1/sr

Links

CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 title 1
206010009944 Colon cancer Diseases 0.000 title 1
208000001333 Colorectal Neoplasms Diseases 0.000 title 1
206010058467 Lung neoplasm malignant Diseases 0.000 title 1
206010061902 Pancreatic neoplasm Diseases 0.000 title 1
RVKNSWDZQDXTPZ-UHFFFAOYSA-N [1,2]thiazolo[3,4-b]pyridine Chemical compound N1=CC=CC2=CSN=C21 RVKNSWDZQDXTPZ-UHFFFAOYSA-N 0.000 title 1
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
210000004072 lung Anatomy 0.000 title 1
201000005202 lung cancer Diseases 0.000 title 1
208000020816 lung neoplasm Diseases 0.000 title 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
201000002528 pancreatic cancer Diseases 0.000 title 1
208000008443 pancreatic carcinoma Diseases 0.000 title 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
GIVUQTUKKWDKHE-UHFFFAOYSA-N pyrido[2,3-d]pyridazine Chemical compound C1=NN=CC2=CC=CN=C21 GIVUQTUKKWDKHE-UHFFFAOYSA-N 0.000 title 1
159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 title 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

RS20211294A 2016-12-22 2017-12-21 Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva RS62456B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662438334P	2016-12-22	2016-12-22
PCT/US2017/067801 WO2018119183A2 (en)	2016-12-22	2017-12-21	Kras g12c inhibitors and methods of using the same
EP17832646.8A EP3558955B1 (en)	2016-12-22	2017-12-21	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer

Publications (1)

Publication Number	Publication Date
RS62456B1 true RS62456B1 (sr)	2021-11-30

Family

ID=61007802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20211294A RS62456B1 (sr)	2016-12-22	2017-12-21	Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva

Country Status (34)

Country	Link
US (3)	US10532042B2 (sr)
EP (2)	EP3558955B1 (sr)
JP (4)	JP6858861B2 (sr)
KR (2)	KR20230150408A (sr)
CN (3)	CN116621833A (sr)
AU (2)	AU2017379074C9 (sr)
BR (1)	BR112019012976A2 (sr)
CA (1)	CA3048217A1 (sr)
CL (2)	CL2019001762A1 (sr)
CO (1)	CO2019006598A2 (sr)
CR (1)	CR20190338A (sr)
CY (1)	CY1125262T1 (sr)
DK (1)	DK3558955T3 (sr)
EA (1)	EA201991528A1 (sr)
ES (1)	ES2894255T3 (sr)
HR (1)	HRP20211642T1 (sr)
HU (1)	HUE056777T2 (sr)
IL (2)	IL267495B (sr)
JO (1)	JOP20190154B1 (sr)
LT (1)	LT3558955T (sr)
MA (1)	MA47107B1 (sr)
MX (1)	MX2019007643A (sr)
MY (1)	MY196830A (sr)
NZ (1)	NZ754994A (sr)
PE (1)	PE20191207A1 (sr)
PH (1)	PH12019501670A1 (sr)
PL (1)	PL3558955T3 (sr)
PT (1)	PT3558955T (sr)
RS (1)	RS62456B1 (sr)
SG (2)	SG11201906223TA (sr)
SI (1)	SI3558955T1 (sr)
UA (1)	UA124474C2 (sr)
WO (1)	WO2018119183A2 (sr)
ZA (1)	ZA201904548B (sr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2018013983A (es)	2016-05-18	2019-08-16	Mirati Therapeutics Inc	Inhibidores g12c de kras.
MA47107B1 (fr)	2016-12-22	2021-11-30	Amgen Inc	Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
IL272512B (en) *	2017-09-08	2022-07-01	Amgen Inc	kras g12c inhibitors and methods of using them
KR20190043437A (ko)	2017-10-18	2019-04-26	씨제이헬스케어 주식회사	단백질 키나제 억제제로서의 헤테로고리 화합물
PL3710439T3 (pl)	2017-11-15	2023-06-26	Mirati Therapeutics, Inc.	Inhibitory kras g12c
US10647715B2 (en)	2017-11-15	2020-05-12	Mirati Therapeutics, Inc.	KRas G12C inhibitors
WO2019141250A1 (zh)	2018-01-19	2019-07-25	南京明德新药研发股份有限公司	作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
MX2020011582A (es)	2018-05-04	2020-11-24	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
CA3098574A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
US11932633B2 (en)	2018-05-07	2024-03-19	Mirati Therapeutics, Inc.	KRas G12C inhibitors
TW202012415A (zh)	2018-05-08	2020-04-01	瑞典商阿斯特捷利康公司	化學化合物
US10988485B2 (en)	2018-05-10	2021-04-27	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
ES2938987T3 (es)	2018-06-01	2023-04-18	Amgen Inc	Inhibidores de KRAS G12c y métodos de uso de los mismos
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
CN112654621A (zh)	2018-06-27	2021-04-13	百时美施贵宝公司	可作为t细胞活化剂的经取代萘啶酮化合物
WO2020006016A1 (en)	2018-06-27	2020-01-02	Bristol-Myers Squibb Company	Naphthyridinone compounds useful as t cell activators
KR102495687B1 (ko)	2018-08-16	2023-02-07	에프. 호프만-라 로슈 아게	융합 고리 화합물
JP2022500388A (ja) *	2018-09-10	2022-01-04	ミラティセラピューティクス，インコーポレイテッド	組み合わせ療法
AU2019344897B2 (en)	2018-09-18	2024-01-18	Nikang Therapeutics, Inc.	Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) *	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020106640A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
EP3894396A1 (en)	2018-12-10	2021-10-20	Ideaya Biosciences, Inc.	2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
JP2022517222A (ja)	2019-01-10	2022-03-07	ミラティセラピューティクス，インコーポレイテッド	Ｋｒａｓｇ１２ｃ阻害剤
JP2022520079A (ja)	2019-02-12	2022-03-28	ノバルティスアーゲー	Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
WO2020173935A1 (en)	2019-02-26	2020-09-03	Boehringer Ingelheim International Gmbh	New isoindolinone substituted indoles and derivatives as ras inhibitors
CN111773225A (zh) *	2019-04-04	2020-10-16	山东轩竹医药科技有限公司	Kras及其突变体表达抑制剂
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
BR112021023277A2 (pt)	2019-05-21	2022-01-04	Amgen Inc	Formas em estado sólido
WO2020234103A1 (en)	2019-05-21	2020-11-26	Bayer Aktiengesellschaft	Identification and use of kras inhibitors
KR20220010542A (ko) *	2019-05-21	2022-01-25	인벤티스바이오 컴퍼니 리미티드	헤테로 고리 화합물, 이의 제조 방법 및 용도
CA3139769A1 (en) *	2019-05-29	2020-12-03	Shiqiang Liu	Nitrogen-containing heterocyclic derivative regulator, preparation method therefor and application thereof
CN112047937B (zh) *	2019-06-06	2023-04-07	劲方医药科技(上海)有限公司	四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
JP2022539341A (ja) *	2019-06-24	2022-09-08	クヮントンニューオップバイオファーマシューティカルズカンパニー，リミテッド	Ｋｒａｓｇ１２ｃの阻害剤としての複素環式化合物
CN110256421A (zh) *	2019-06-26	2019-09-20	微境生物医药科技(上海)有限公司	Kras-g12c抑制剂
CN112300173B (zh) *	2019-07-30	2021-10-01	上海凌达生物医药有限公司	一类含氮多环类化合物、制备方法和用途
MX2022001421A (es) *	2019-08-02	2022-06-08	Shanghai Jemincare Pharmaceuticals Co Ltd	Compuesto tetracíclico, método de preparación y uso del mismo.
WO2021023247A1 (en) *	2019-08-07	2021-02-11	Jacobio Pharmaceuticals Co., Ltd.	Kras mutant protein inhibitor
AR119821A1 (es)	2019-08-28	2022-01-12	Bristol Myers Squibb Co	Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4021444A4 (en)	2019-08-29	2023-01-04	Mirati Therapeutics, Inc.	G12D KRAS INHIBITORS
WO2021061749A1 (en) *	2019-09-24	2021-04-01	Mirati Therapeutics, Inc.	Combination therapies
CN112552295A (zh) *	2019-09-25	2021-03-26	北京加科思新药研发有限公司	Kras突变蛋白抑制剂
WO2021076655A1 (en)	2019-10-15	2021-04-22	Amgen Inc.	Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
MX2022004656A (es)	2019-10-24	2022-05-25	Amgen Inc	Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
WO2021086833A1 (en) *	2019-10-28	2021-05-06	Merck Sharp & Dohme Corp.	Small molecule inhibitors of kras g12c mutant
AU2020379734A1 (en)	2019-11-04	2022-05-05	Revolution Medicines, Inc.	Ras inhibitors
TW202132315A (zh)	2019-11-04	2021-09-01	美商銳新醫藥公司	Ras 抑制劑
CN114867735A (zh)	2019-11-04	2022-08-05	锐新医药公司	Ras抑制剂
CN114980976A (zh)	2019-11-27	2022-08-30	锐新医药公司	共价ras抑制剂及其用途
CN111377918B (zh) *	2019-11-29	2021-03-02	苏州信诺维医药科技有限公司	一种kras抑制剂化合物
US20230028414A1 (en)	2019-12-16	2023-01-26	Amgen Inc.	Dosing regimen of kras g12c inhibitor
WO2021120045A1 (en)	2019-12-18	2021-06-24	InventisBio Co., Ltd.	Heterocyclic compounds, preparation methods and uses thereof
WO2021120890A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Pyrazolyl derivatives useful as anti-cancer agents
IL294048A (en)	2019-12-20	2022-08-01	Mirati Therapeutics Inc	sos1 inhibitors
CN114671866A (zh) *	2020-12-25	2022-06-28	苏州泽璟生物制药股份有限公司	芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021150613A1 (en)	2020-01-20	2021-07-29	Incyte Corporation	Spiro compounds as inhibitors of kras
GB202001344D0 (en)	2020-01-31	2020-03-18	Redx Pharma Plc	Ras Inhibitors
CN112159405B (zh) *	2020-02-04	2021-09-14	广州必贝特医药技术有限公司	吡啶并嘧啶酮类化合物及其应用
CN113248521B (zh) *	2020-02-11	2023-07-18	上海和誉生物医药科技有限公司	一种k-ras g12c抑制剂及其制备方法和应用
WO2021169963A1 (zh) *	2020-02-24	2021-09-02	上海喆邺生物科技有限公司	芳香类化合物及其在制备抗肿瘤药物中的应用
CN114901663A (zh) *	2020-03-02	2022-08-12	上海喆邺生物科技有限公司	一类芳香杂环类化合物及其在药物中的应用
CN111358794A (zh) *	2020-03-13	2020-07-03	南通大学	一种用于治疗非小细胞肺癌的药物或试剂盒
TW202144345A (zh)	2020-03-17	2021-12-01	大陸商北京加科思新藥研發有限公司	Ｋｒａｓ突變蛋白抑制劑
JP7461499B2 (ja) *	2020-04-03	2024-04-03	メッドシャインディスカバリーインコーポレイテッド	オクタヒドロピラジノジアザナフチリジンジオン化合物
US11739102B2 (en)	2020-05-13	2023-08-29	Incyte Corporation	Fused pyrimidine compounds as KRAS inhibitors
CN112574199B (zh) *	2020-05-20	2021-05-18	首药控股(北京)股份有限公司	Kras-G12C抑制剂杂环化合物
BR112022023462A2 (pt) *	2020-06-02	2022-12-20	Boehringer Ingelheim Int	2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer
TW202210633A (zh)	2020-06-05	2022-03-16	法商昂席歐公司	用於治療癌症之dbait分子與kras抑制劑的組合
WO2021249563A1 (zh) *	2020-06-12	2021-12-16	苏州泽璟生物制药股份有限公司	芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115916194A (zh)	2020-06-18	2023-04-04	锐新医药公司	用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
WO2022017339A1 (zh) *	2020-07-20	2022-01-27	江苏恒瑞医药股份有限公司	稠合哒嗪类衍生物、其制备方法及其在医药上的应用
WO2022028346A1 (zh) *	2020-08-02	2022-02-10	上海喆邺生物科技有限公司	一种芳香类化合物及其在抗肿瘤药物中的应用
WO2022037560A1 (zh) *	2020-08-21	2022-02-24	广东东阳光药业有限公司	嘧啶酮衍生物及其在药物中的应用
KR102560912B1 (ko)	2020-08-26	2023-07-28	한양대학교 에리카산학협력단	엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물
US20220064188A1 (en) *	2020-08-28	2022-03-03	Incyte Corporation	Vinyl imidazole compounds as inhibitors of kras
CN116209438A (zh)	2020-09-03	2023-06-02	锐新医药公司	使用sos1抑制剂治疗具有shp2突变的恶性疾病
CN116457358A (zh)	2020-09-15	2023-07-18	锐新医药公司	作为ras抑制剂以治疗癌症的吲哚衍生物
CN116323624A (zh) *	2020-09-30	2023-06-23	上海医药集团股份有限公司	一种喹唑啉类化合物及其应用
WO2022072783A1 (en)	2020-10-02	2022-04-07	Incyte Corporation	Bicyclic dione compounds as inhibitors of kras
WO2022111521A1 (zh) *	2020-11-24	2022-06-02	杭州多域生物技术有限公司	一种芳香化合物、其制备方法及应用
WO2022121839A1 (zh) *	2020-12-08	2022-06-16	上海和誉生物医药科技有限公司	吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用
WO2022127847A1 (zh) *	2020-12-17	2022-06-23	广东东阳光药业有限公司	嘧啶酮衍生物及其在药物中的应用
WO2022133345A1 (en)	2020-12-18	2022-06-23	Erasca, Inc.	Tricyclic pyridones and pyrimidones
WO2022140246A1 (en)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
CN116648250A (zh) *	2020-12-22	2023-08-25	韩美药品株式会社	作为sos1抑制剂的新型喹唑啉衍生物及其用途
IL303661A (en)	2020-12-22	2023-08-01	Nikang Therapeutics Inc	COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY
CN115124533A (zh) *	2021-03-26	2022-09-30	浙江海正药业股份有限公司	四环类衍生物、其制备方法和其医药上的用途
EP4322945A2 (en) *	2021-04-16	2024-02-21	Mirati Therapeutics, Inc.	Kras g12c inhibitors
TW202309052A (zh)	2021-05-05	2023-03-01	美商銳新醫藥公司	Ｒａｓ抑制劑
IL308195A (en)	2021-05-05	2024-01-01	Revolution Medicines Inc	RAS inhibitors for cancer treatment
WO2022266206A1 (en)	2021-06-16	2022-12-22	Erasca, Inc.	Kras inhibitor conjugates
TW202317100A (zh)	2021-06-23	2023-05-01	瑞士商諾華公司	包含ｋｒａｓｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
CN117425649A (zh)	2021-06-23	2024-01-19	诺华股份有限公司	作为kras突变蛋白抑制剂的吡唑衍生物
WO2023284730A1 (en)	2021-07-14	2023-01-19	Nikang Therapeutics, Inc.	Alkylidene derivatives as kras inhibitors
WO2023031781A1 (en)	2021-09-01	2023-03-09	Novartis Ag	Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AU2022349569A1 (en)	2021-09-22	2024-04-04	Sichuan Huiyu Pharmaceutical Co., Ltd.	Pyridine derivative and use thereof
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023064857A1 (en)	2021-10-14	2023-04-20	Incyte Corporation	Quinoline compounds as inhibitors of kras
WO2023078252A1 (en)	2021-11-02	2023-05-11	Flare Therapeutics Inc.	Pparg inverse agonists and uses thereof
WO2023099592A1 (en) *	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023114954A1 (en)	2021-12-17	2023-06-22	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
CN116332960A (zh) *	2021-12-23	2023-06-27	上海优理惠生医药有限公司	一种哒嗪类化合物、其药物组合物及应用
WO2023152255A1 (en)	2022-02-10	2023-08-17	Bayer Aktiengesellschaft	Fused pyrimidines as kras inhibitors
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
WO2023192801A1 (en)	2022-03-28	2023-10-05	Nikang Therapeutics, Inc.	Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023194310A1 (en)	2022-04-04	2023-10-12	Sanofi	Therapeutic combination of kras g12c inhibitor and tead inhibitor
WO2023199180A1 (en)	2022-04-11	2023-10-19	Novartis Ag	Therapeutic uses of a krasg12c inhibitor
WO2023240024A1 (en)	2022-06-08	2023-12-14	Nikang Therapeutics, Inc.	Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2023240253A2 (en) *	2022-06-10	2023-12-14	Forward Therapeutics, Inc.	Modulators of tnf-alpha activity
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024040131A1 (en)	2022-08-17	2024-02-22	Treeline Biosciences, Inc.	Pyridopyrimidine kras inhibitors
GB202212641D0 (en)	2022-08-31	2022-10-12	Jazz Pharmaceuticals Ireland Ltd	Novel compounds

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4450150A (en)	1973-05-17	1984-05-22	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4232027A (en)	1979-01-29	1980-11-04	E. R. Squibb & Sons, Inc.	1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
EP0090505B1 (en)	1982-03-03	1990-08-08	Genentech, Inc.	Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
JP2762522B2 (ja)	1989-03-06	1998-06-04	藤沢薬品工業株式会社	血管新生阻害剤
US5112946A (en)	1989-07-06	1992-05-12	Repligen Corporation	Modified pf4 compositions and methods of use
PT98990A (pt)	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5892112A (en)	1990-11-21	1999-04-06	Glycomed Incorporated	Process for preparing synthetic matrix metalloprotease inhibitors
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
DE69222637T2 (de)	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5151413A (en)	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en)	1991-12-03	1992-01-29	Smithkline Beecham Plc	Novel compound
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
US5256790A (en)	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
CA2148484A1 (en)	1992-11-13	1994-05-26	Stewart Lyman	Novel cytokine designated elk ligand
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5516658A (en)	1993-08-20	1996-05-14	Immunex Corporation	DNA encoding cytokines that bind the cell surface receptor hek
CA2148931A1 (en)	1993-10-01	1995-04-13	Jurg Zimmermann	Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2175215C (en)	1993-11-19	2008-06-03	Yat Sun Or	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
CN1046944C (zh)	1993-12-17	1999-12-01	山道士有限公司	雷怕霉素类衍生物
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995028484A1 (en)	1994-04-15	1995-10-26	Amgen Inc.	Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
ATE159257T1 (de)	1994-05-03	1997-11-15	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer wirkung
US6303769B1 (en)	1994-07-08	2001-10-16	Immunex Corporation	Lerk-5 dna
US5919905A (en)	1994-10-05	1999-07-06	Immunex Corporation	Cytokine designated LERK-6
US6057124A (en)	1995-01-27	2000-05-02	Amgen Inc.	Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
ATE446955T1 (de)	1995-03-30	2009-11-15	Pfizer Prod Inc	Chinazolinone derivate
JP4249804B2 (ja)	1995-04-03	2009-04-08	ノバルティス・アクチエンゲゼルシャフト	ピラゾール誘導体およびその製造法
CA2218503C (en)	1995-04-20	2001-07-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5650415A (en)	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
CA2219659C (en)	1995-06-09	2008-03-18	Novartis Ag	Rapamycin derivatives
DE69619114T2 (de)	1995-07-06	2002-10-02	Novartis Ag	Pyrolopyrimidine und verfahren zu ihrer herstellung
DE19534177A1 (de)	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
DK0780386T3 (da)	1995-12-20	2003-02-03	Hoffmann La Roche	Matrixmetalloproteaseinhibitorer
EP0888349B1 (en)	1996-01-23	2002-05-22	Novartis AG	Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja)	1996-01-30	2003-05-12	東レ・ダウコーニング・シリコーン株式会社	シリコーンゴム組成物
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
DE19608588A1 (de)	1996-03-06	1997-09-11	Thomae Gmbh Dr K	Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19629652A1 (de)	1996-03-06	1998-01-29	Thomae Gmbh Dr K	4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DK0888353T3 (da)	1996-03-15	2003-10-27	Novartis Ag	N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
NZ332119A (en)	1996-04-12	2001-08-31	Warner Lambert Co	Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
GB9607729D0 (en)	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
BR9709959A (pt)	1996-06-24	2000-05-09	Pfizer	Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
EP0818442A3 (en)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
AR007857A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID19430A (id)	1996-07-13	1998-07-09	Glaxo Group Ltd	Senyawa senyawa heterosiklik
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
TR199900066T2 (xx)	1996-07-18	1999-04-21	Pfizer Inc.	Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
US6111090A (en)	1996-08-16	2000-08-29	Schering Corporation	Mammalian cell surface antigens; related reagents
ATE397660T1 (de)	1996-08-16	2008-06-15	Schering Corp	Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
PT938486E (pt)	1996-08-23	2008-03-27	Novartis Ag	Pirrolopirimidinas substituídas e processos para a sua preparação
IL128189A0 (en)	1996-08-23	1999-11-30	Pfizer	Arylsulfonylamino hydroxamic acid derivatives
WO1998014450A1 (en)	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
WO1998014449A1 (en)	1996-10-02	1998-04-09	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
GB9621757D0 (en)	1996-10-18	1996-12-11	Ciba Geigy Ag	Phenyl-substituted bicyclic heterocyclyl derivatives and their use
US6077864A (en)	1997-01-06	2000-06-20	Pfizer Inc.	Cyclic sulfone derivatives
PL335027A1 (en)	1997-02-03	2000-03-27	Pfizer Prod Inc	Derivatives of arylsulphonylamino hydroxamic acid
DE69839338T2 (de)	1997-02-05	2008-07-10	Warner-Lambert Company Llc	Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
CA2279863A1 (en)	1997-02-07	1998-08-13	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
BR9807678A (pt)	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6150395A (en)	1997-05-30	2000-11-21	The Regents Of The University Of California	Indole-3-carbinol (I3C) derivatives and methods
AU8689298A (en)	1997-08-05	1999-03-01	Sugen, Inc.	Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
KR100372138B1 (ko)	1997-08-08	2003-02-14	화이자 프로덕츠 인코포레이티드	아릴옥시아릴설포닐아미노 하이드록삼산 유도체
AU1102399A (en)	1997-10-21	1999-05-10	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
CA2319236A1 (en)	1998-02-09	1999-08-12	Genentech, Inc.	Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
EP1066286B1 (en)	1998-03-04	2009-04-29	Bristol-Myers Squibb Company	Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
IL139934A (en)	1998-05-29	2007-10-31	Sugen Inc	History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
UA60365C2 (uk)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP2002520324A (ja)	1998-07-10	2002-07-09	メルクエンドカムパニーインコーポレーテッド	新規な血管形成インヒビター
EP1109555A4 (en)	1998-08-31	2001-11-21	Merck & Co Inc	NEW ANGIOGENIC INHIBITORS
PT1004578E (pt)	1998-11-05	2004-06-30	Pfizer Prod Inc	Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
IL144144A0 (en)	1999-01-13	2002-05-23	Bayer Ag	Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP1165085B1 (en)	1999-03-30	2006-06-14	Novartis AG	Phthalazine derivatives for treating inflammatory diseases
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
US6521424B2 (en)	1999-06-07	2003-02-18	Immunex Corporation	Recombinant expression of Tek antagonists
DK1187918T4 (da)	1999-06-07	2009-02-23	Immunex Corp	TEK-antagonister
DE60036945T2 (de)	1999-07-12	2008-08-21	Genentech, Inc., South San Francisco	Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
AU783158B2 (en)	1999-08-24	2005-09-29	Ariad Pharmaceuticals, Inc.	28-epirapalogs
EE05330B1 (et)	1999-11-05	2010-08-16	Astrazeneca Ab	Kinasoliini derivaadid kui VEGF-i inhibiitorid
ATE514676T1 (de)	1999-11-24	2011-07-15	Sugen Inc	Ionisierbare indolinon derivate und deren verwendung als ptk liganden
US6515004B1 (en)	1999-12-15	2003-02-04	Bristol-Myers Squibb Company	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en)	1999-12-20	2004-04-27	Immunex Corporation	TWEAK receptor
NZ521437A (en)	2000-02-25	2004-04-30	Immunex Corp	Integrin antagonists suitable as inhibitors of angiogenesis
US6630500B2 (en)	2000-08-25	2003-10-07	Cephalon, Inc.	Selected fused pyrrolocarbazoles
IL156306A0 (en)	2000-12-21	2004-01-04	Glaxo Group Ltd	Pyrimidineamines as angiogenesis modulators
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20020147198A1 (en)	2001-01-12	2002-10-10	Guoqing Chen	Substituted arylamine derivatives and methods of use
US7102009B2 (en)	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
US7105682B2 (en)	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
US6995162B2 (en)	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20050026868A1 (en)	2003-07-11	2005-02-03	Metcalf Chester A.	Phosphorus-containing macrocycles
JP2002233610A (ja)	2002-02-18	2002-08-20	Olympia:Kk	スロットマシン
US7307088B2 (en)	2002-07-09	2007-12-11	Amgen Inc.	Substituted anthranilic amide derivatives and methods of use
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
RU2369636C2 (ru)	2003-05-23	2009-10-10	Уайт	Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
CA2531454C (en)	2003-07-08	2011-10-25	Novartis Ag	Use of rapamycin and rapamycin derivatives for the treatment of bone loss
US20050048054A1 (en)	2003-07-11	2005-03-03	Shino Hanabuchi	Lymphocytes; methods
AR045134A1 (es)	2003-07-29	2005-10-19	Smithkline Beecham Plc	Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
BRPI0413695A (pt)	2003-08-22	2006-10-24	Avanir Pharmaceuticals	derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
WO2005055808A2 (en)	2003-12-02	2005-06-23	Genzyme Corporation	Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
US20060002932A1 (en)	2004-06-04	2006-01-05	Duke University	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
DK1786785T3 (da)	2004-08-26	2010-05-31	Pfizer	Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
PE20060608A1 (es)	2004-10-13	2006-08-22	Wyeth Corp	Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
PT1866339E (pt)	2005-03-25	2013-09-03	Gitr Inc	Moléculas de ligação a gitr e suas utilizações
KR101339628B1 (ko)	2005-05-09	2013-12-09	메다렉스, 인코포레이티드	예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US20090012085A1 (en)	2005-09-20	2009-01-08	Charles Michael Baum	Dosage forms and methods of treatment using a tyrosine kinase inhibitor
US20110212086A1 (en)	2006-01-19	2011-09-01	Genzyme Corporation	GITR Antibodies For The Treatment of Cancer
CL2007003520A1 (es)	2006-12-07	2008-08-22	Piramed Ltd Genentech Inc	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
WO2009009116A2 (en)	2007-07-12	2009-01-15	Tolerx, Inc.	Combination therapies employing gitr binding molecules
KR101584823B1 (ko)	2007-09-12	2016-01-22	제넨테크, 인크.	포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
US8354528B2 (en)	2007-10-25	2013-01-15	Genentech, Inc.	Process for making thienopyrimidine compounds
US20110177070A1 (en)	2008-07-02	2011-07-21	Emergent Product Development Seatlle, LLC	TGF-Beta Antagonist Multi-Target Binding Proteins
WO2010030002A1 (ja)	2008-09-12	2010-03-18	国立大学法人三重大学	外来性ｇｉｔｒリガンド発現細胞
EP2266984A1 (en) *	2009-06-26	2010-12-29	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
IN2015DN02826A (sr)	2009-09-03	2015-09-11	Merck Sharp & Dohme
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
CN102108078B (zh) *	2009-12-24	2013-10-30	沈阳药科大学	1,4-取代酞嗪类化合物及其制备方法和用途
AU2010343056A1 (en)	2009-12-29	2012-08-02	Emergent Product Development Seattle, Llc	Ron binding constructs and methods of use thereof
EP2696682B1 (en) *	2011-04-13	2018-03-21	Innovimmune Biotherapeutics, Inc.	Mif inhibitors and their uses
WO2013039954A1 (en)	2011-09-14	2013-03-21	Sanofi	Anti-gitr antibodies
US20150087628A1 (en)	2012-04-10	2015-03-26	The Regents Of The University Of California	Compositions and methods for treating cancer
TW201524952A (zh)	2013-03-15	2015-07-01	Araxes Pharma Llc	Ｋｒａｓｇ１２ｃ之共價抑制劑
US9745319B2 (en)	2013-03-15	2017-08-29	Araxes Pharma Llc	Irreversible covalent inhibitors of the GTPase K-Ras G12C
UY35464A (es)	2013-03-15	2014-10-31	Araxes Pharma Llc	Inhibidores covalentes de kras g12c.
GB201312059D0 (en) *	2013-07-05	2013-08-21	Univ Leuven Kath	Novel GAK modulators
JP6559123B2 (ja)	2013-10-10	2019-08-14	アラクセスファーマエルエルシー	Ｋｒａｓｇ１２ｃの阻害剤
JO3805B1 (ar) *	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
CA2936559C (en) *	2014-01-20	2019-03-12	Cleave Biosciences, Inc.	Fused pyrimidines as inhibitors of p97 complex
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
WO2016049565A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Compositions and methods for inhibition of ras
WO2016049568A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Methods and compositions for inhibition of ras
ES2826443T3 (es)	2014-09-25	2021-05-18	Araxes Pharma Llc	Inhibidores de proteínas mutantes KRAS G12C
TW201702232A (zh) *	2015-04-10	2017-01-16	亞瑞克西斯製藥公司	經取代之喹唑啉化合物及其使用方法
CA2982360A1 (en)	2015-04-15	2016-10-20	Liansheng Li	Fused-tricyclic inhibitors of kras and methods of use thereof
MX2018000777A (es)	2015-07-22	2018-03-23	Araxes Pharma Llc	Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
WO2017058768A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356339A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10875842B2 (en)	2015-09-28	2020-12-29	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US10975071B2 (en)	2015-09-28	2021-04-13	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
TW201726656A (zh)	2015-11-16	2017-08-01	亞瑞克西斯製藥公司	包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en)	2015-12-09	2017-06-15	Araxes Pharma Llc	Methods for preparation of quinazoline derivatives
WO2017172979A1 (en)	2016-03-30	2017-10-05	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
MX2018013983A (es)	2016-05-18	2019-08-16	Mirati Therapeutics Inc	Inhibidores g12c de kras.
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en)	2016-09-29	2018-04-05	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
WO2018068017A1 (en)	2016-10-07	2018-04-12	Araxes Pharma Llc	Heterocyclic compounds as inhibitors of ras and methods of use thereof
MA47107B1 (fr)	2016-12-22	2021-11-30	Amgen Inc	Dérivés de benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine et pyrido[2,3-d]pyrimidine en tant qu'inhibiteurs de kras g12c pour le traitement de cancer du poumon, du pancréas ou de l'intestin
US20200385364A1 (en)	2017-01-26	2020-12-10	Araxes Pharma Llc	Fused n-heterocyclic compounds and methods of use thereof
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
EP3630747A1 (en)	2017-05-25	2020-04-08	Araxes Pharma LLC	Quinazoline derivatives as modulators of mutant kras, hras or nras
IL272512B (en)	2017-09-08	2022-07-01	Amgen Inc	kras g12c inhibitors and methods of using them
CA3098574A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MX2020011582A (es)	2018-05-04	2020-11-24	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
US10988485B2 (en)	2018-05-10	2021-04-27	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
ES2938987T3 (es)	2018-06-01	2023-04-18	Amgen Inc	Inhibidores de KRAS G12c y métodos de uso de los mismos
US20190375749A1 (en)	2018-06-11	2019-12-12	Amgen Inc.	Kras g12c inhibitors and methods of using the same
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
ES2927355T3 (es)	2018-06-21	2022-11-04	Janssen Pharmaceutica Nv	Compuestos inhibidores de OGA
AU2019291101A1 (en)	2018-06-21	2021-01-07	Janssen Pharmaceutica Nv	OGA inhibitor compounds
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
BR112021023277A2 (pt)	2019-05-21	2022-01-04	Amgen Inc	Formas em estado sólido
EP3972972A1 (en)	2019-05-21	2022-03-30	Amgen Inc.	Solid state forms
MX2022004656A (es)	2019-10-24	2022-05-25	Amgen Inc	Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
US20230028414A1 (en)	2019-12-16	2023-01-26	Amgen Inc.	Dosing regimen of kras g12c inhibitor

2017
- 2017-12-21 MA MA47107A patent/MA47107B1/fr unknown
- 2017-12-21 SG SG11201906223TA patent/SG11201906223TA/en unknown
- 2017-12-21 WO PCT/US2017/067801 patent/WO2018119183A2/en unknown
- 2017-12-21 LT LTEPPCT/US2017/067801T patent/LT3558955T/lt unknown
- 2017-12-21 KR KR1020237035546A patent/KR20230150408A/ko active Application Filing
- 2017-12-21 HU HUE17832646A patent/HUE056777T2/hu unknown
- 2017-12-21 CR CR20190338A patent/CR20190338A/es unknown
- 2017-12-21 MY MYPI2019004551A patent/MY196830A/en unknown
- 2017-12-21 CN CN202310364215.0A patent/CN116621833A/zh active Pending
- 2017-12-21 PL PL17832646T patent/PL3558955T3/pl unknown
- 2017-12-21 JO JOP/2019/0154A patent/JOP20190154B1/ar active
- 2017-12-21 SI SI201730951T patent/SI3558955T1/sl unknown
- 2017-12-21 MX MX2019007643A patent/MX2019007643A/es unknown
- 2017-12-21 US US15/849,905 patent/US10532042B2/en active Active
- 2017-12-21 CN CN201780087190.7A patent/CN110366550A/zh active Pending
- 2017-12-21 BR BR112019012976A patent/BR112019012976A2/pt unknown
- 2017-12-21 ES ES17832646T patent/ES2894255T3/es active Active
- 2017-12-21 DK DK17832646.8T patent/DK3558955T3/da active
- 2017-12-21 RS RS20211294A patent/RS62456B1/sr unknown
- 2017-12-21 CA CA3048217A patent/CA3048217A1/en active Pending
- 2017-12-21 CN CN202310364214.6A patent/CN116606261A/zh active Pending
- 2017-12-21 HR HRP20211642TT patent/HRP20211642T1/hr unknown
- 2017-12-21 KR KR1020197020877A patent/KR102592246B1/ko active IP Right Grant
- 2017-12-21 EA EA201991528A patent/EA201991528A1/ru unknown
- 2017-12-21 JP JP2019534162A patent/JP6858861B2/ja active Active
- 2017-12-21 UA UAA201908270A patent/UA124474C2/uk unknown
- 2017-12-21 SG SG10201913491PA patent/SG10201913491PA/en unknown
- 2017-12-21 AU AU2017379074A patent/AU2017379074C9/en active Active
- 2017-12-21 PE PE2019001307A patent/PE20191207A1/es unknown
- 2017-12-21 PT PT178326468T patent/PT3558955T/pt unknown
- 2017-12-21 EP EP17832646.8A patent/EP3558955B1/en active Active
- 2017-12-21 EP EP21183032.8A patent/EP4001269A1/en active Pending
- 2017-12-21 NZ NZ754994A patent/NZ754994A/en unknown
2019
- 2019-06-19 IL IL267495A patent/IL267495B/en unknown
- 2019-06-20 CO CONC2019/0006598A patent/CO2019006598A2/es unknown
- 2019-06-21 CL CL2019001762A patent/CL2019001762A1/es unknown
- 2019-07-11 ZA ZA2019/04548A patent/ZA201904548B/en unknown
- 2019-07-18 PH PH12019501670A patent/PH12019501670A1/en unknown
- 2019-11-05 US US16/675,121 patent/US11285135B2/en active Active
2020
- 2020-03-26 CL CL2020000784A patent/CL2020000784A1/es unknown
2021
- 2021-03-24 JP JP2021049530A patent/JP7073554B2/ja active Active
- 2021-10-13 IL IL287223A patent/IL287223B2/en unknown
- 2021-11-02 CY CY20211100937T patent/CY1125262T1/el unknown
2022
- 2022-01-31 US US17/589,163 patent/US20220168280A1/en not_active Abandoned
- 2022-05-10 JP JP2022077379A patent/JP7373014B2/ja active Active
- 2022-06-09 AU AU2022204026A patent/AU2022204026A1/en active Pending
2023
- 2023-10-19 JP JP2023180046A patent/JP2024010022A/ja active Pending

Also Published As

Publication number	Publication date
US11285135B2 (en)	2022-03-29
AU2017379074B2 (en)	2022-03-17
CA3048217A1 (en)	2018-06-28
ES2894255T3 (es)	2022-02-14
CR20190338A (es)	2019-09-09
UA124474C2 (uk)	2021-09-22
CL2019001762A1 (es)	2019-10-18
CN116606261A (zh)	2023-08-18
EP3558955A2 (en)	2019-10-30
IL267495B (en)	2021-10-31
JP2020504738A (ja)	2020-02-13
EP4001269A1 (en)	2022-05-25
SG10201913491PA (en)	2020-03-30
MX2019007643A (es)	2019-09-09
WO2018119183A3 (en)	2018-08-23
PE20191207A1 (es)	2019-09-10
US20220168280A1 (en)	2022-06-02
PH12019501670A1 (en)	2019-11-04
DK3558955T3 (da)	2021-10-25
US20180177767A1 (en)	2018-06-28
IL267495A (en)	2019-08-29
HRP20211642T1 (hr)	2022-01-21
CN110366550A (zh)	2019-10-22
CL2020000784A1 (es)	2020-08-28
AU2017379074C1 (en)	2023-05-25
SI3558955T1 (sl)	2021-12-31
WO2018119183A2 (en)	2018-06-28
MA47107B1 (fr)	2021-11-30
ZA201904548B (en)	2020-03-25
MA47107A (fr)	2021-03-31
PL3558955T3 (pl)	2021-12-27
EA201991528A1 (ru)	2020-01-16
KR20230150408A (ko)	2023-10-30
AU2017379074A1 (en)	2019-07-18
BR112019012976A2 (pt)	2019-12-31
IL287223B1 (en)	2023-04-01
CY1125262T1 (el)	2023-06-09
AU2017379074C9 (en)	2023-06-08
PT3558955T (pt)	2021-10-19
SG11201906223TA (en)	2019-08-27
CO2019006598A2 (es)	2019-06-28
HUE056777T2 (hu)	2022-03-28
AU2022204026A1 (en)	2022-06-30
JP7073554B2 (ja)	2022-05-23
EP3558955B1 (en)	2021-08-11
IL287223B2 (en)	2023-08-01
NZ754994A (en)	2022-12-23
IL287223A (en)	2021-12-01
KR102592246B1 (ko)	2023-10-23
JP2024010022A (ja)	2024-01-23
JP7373014B2 (ja)	2023-11-01
KR20190097201A (ko)	2019-08-20
LT3558955T (lt)	2021-11-10
CN116621833A (zh)	2023-08-22
US10532042B2 (en)	2020-01-14
JP2021100960A (ja)	2021-07-08
JP6858861B2 (ja)	2021-04-14
JP2022110053A (ja)	2022-07-28
US20200069657A1 (en)	2020-03-05
JOP20190154A1 (ar)	2019-06-23
MY196830A (en)	2023-05-03
JOP20190154B1 (ar)	2022-09-15

Publication	Publication Date	Title
ZA201904548B (en)	2020-03-25	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
PH12018500792A1 (en)	2018-10-01	Benzolactam compounds as protein kinase inhibitors
IL266245B (en)	2021-05-31	History of 9,8,7,6-tetrahydro-3h-pyrazolo[3,4-f]isoquinoline useful in cancer treatment
HK1255598A1 (zh)	2019-08-23	咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
HK1257413A1 (zh)	2019-10-18	用於治療癌症的、為共濟失調毛細血管擴張症突變型(atm)激酶的選擇性調節劑的8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-異丙基-咪唑並[4，5-c]喹啉-2-酮衍生物
EP3268000A4 (en)	2018-08-22	Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
PL3712152T3 (pl)	2021-08-02	Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
PT3371185T (pt)	2020-12-28	Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
MY185392A (en)	2021-05-17	Jak1 inhibitors for the treatment of myelodysplastic syndromes
HK1257677A1 (zh)	2019-10-25	咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
IL293093B1 (en)	2024-03-01	The use of pyrimidine and pyridine history in the treatment of cancer
IL258707A (en)	2018-06-28	6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
WO2014153464A3 (en)	2014-11-27	2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
RS62937B1 (sr)	2022-03-31	Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina korisni u tretmanu raka
NZ629877A (en)	2015-12-24	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use